30.12.2014 Views

Rheumatoid Arthritis

Rheumatoid Arthritis

Rheumatoid Arthritis

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Rheumatoid</strong> <strong>Arthritis</strong><br />

June 6, 2011<br />

Deborah S. Collier, MD<br />

Rheumatology Unit<br />

Massachusetts General Hospital<br />

Harvard Medical School


I have<br />

no industry<br />

sponsorship or<br />

affiliations


Focus of today’s review<br />

• Overview<br />

• 7 questions for patient with RA to PCP


<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Epidemiology<br />

• Systemic inflammatory arthritis than can also involve<br />

internal organs<br />

• Female: male ratio = 2.5:1<br />

• Prevalence ~ 1%, peak 30 – 55 years old<br />

• Genetic predisposition (HLA-DRB1)<br />

• Environmental risk factors: cigarette smoking, infection<br />

• Shortens life span, causes disability<br />

de Vries N, et al. <strong>Arthritis</strong> Rheum 2002 Apr;46(4):921-8. Pincus T, et al. J Rheumatol. 1989<br />

Klareskog L , et al. <strong>Arthritis</strong> Rheum. 2006;54:38-46. Pincus T, et al. J Rheumatol. 1987.


<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Clinical Features<br />

• Symmetrical polyarthritis<br />

• Morning stiffness<br />

- Lasting ≥ 1 hour<br />

• <strong>Rheumatoid</strong> nodules<br />

• Limited range of motion<br />

• Extraarticular involvement:<br />

eye, lung, heart, muscle,<br />

vasculature


RA: Erosive <strong>Arthritis</strong>


<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Treatment<br />

Then…<br />

…and Now


History of DMARD* Use in the United States<br />

Anti-IL6<br />

↓ T-cell activation<br />

Anti-CD20<br />

Tocilizumab<br />

Abatacept<br />

Rituximab<br />

Anti-TNF Etanercept, Infliximab, Adalimumab, Certolizumab, Golimumab<br />

Leflunomide<br />

Methotrexate<br />

Penicillamine<br />

Sulfasalazine<br />

Antimalarials<br />

Aspirin Cortisone<br />

Gold<br />

1900<br />

1940 1950 1960 1970 1980 1990 2000<br />

2010<br />

*DMARD = Disease Modifying Anti-Rheumatic Drug<br />

= biologic


<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Treatment<br />

…from first suspicion in<br />

PCP’s office to optimal<br />

treatment by rheumatologist<br />

in 6-12 months…


7 RA questions from patient to PCP…<br />

• risk factors for RA<br />

• adverse effects of DMARDs (disease modifying antirheumatic<br />

drugs)<br />

• safety of immunizations in patients on DMARDs<br />

• Safety of biologics in patients with hepatitis


My mother has RA. Are there<br />

any life style changes that I can<br />

make to avoid getting it myself<br />

A. loose weight<br />

B. quit smoking<br />

C. keep immunizations up to date<br />

D. all of the above


My mother has RA. Are there<br />

any life style changes that I can<br />

make to avoid getting it myself<br />

A. lose weight<br />

B. quit smoking<br />

C. keep immunizations up to date<br />

D. all of the above


Smoking and RA<br />

- RR of developing RA = 1.4 for women who smoke >25 cigarettes a<br />

day, compared to non-smokers<br />

- In HLA-DRB4 (+) patients, RR of developing RA is 5.6 in smokers,<br />

compared to non-smokers<br />

- RA patients with > 25 pack year history are more likely to be seropositive,<br />

have nodules, have bony erosion<br />

- Risk of developing RA returns to baseline 10 years after quitting<br />

smoking<br />

Karlson, <strong>Arthritis</strong> Rheum 1999. Padyokuv, <strong>Arthritis</strong> Rheum 2004.<br />

Saag, Ann Rheum Dis 1997. Criswell, Am J Med 2002.


What are the risks of being on a<br />

biologic medication for RA


Toxicities of Biologics<br />

TNF’s, rituximab, adalimumab<br />

• Injection site/infusion reactions<br />

• Serious infections<br />

• Opportunistic infections (TB, fungal)<br />

• Malignancy<br />

Rituximab specific<br />

• Progressive multifocal leukoencephalopathy (PML)<br />

Anti-TNF specific<br />

• Demyelination (MS-like syndrome)<br />

• Drug-induced lupus<br />

• Congestive heart failure<br />

Ellerin, <strong>Arthritis</strong> Rheum. 2003.<br />

Mohan, <strong>Arthritis</strong> Rheum 2001.<br />

Kwon, Ann Intern Med 2003.


Serious Infections in Pt’s on Biologics<br />

Bacteria<br />

Streptococccus pneumoniae<br />

Listeria monocytogenes<br />

Mycobacteria<br />

Mycobacterium tuberculosis *<br />

Mycobacterium aviumintracellulare<br />

(MAC)<br />

Fungi<br />

Candida albicans<br />

Pneumocystis jiroveci<br />

Aspergillus fumigatus<br />

Histoplasma capsulatum<br />

Cryptococcus neoformans<br />

Coccidioides immitis<br />

* make sure pt is PPD (-)<br />

Ellerin, <strong>Arthritis</strong> Rheum. 2003.


I am on etanercept for my RA.<br />

Is it true that this drug can<br />

cause cancer<br />

You tell the patient:<br />

A.Anti-TNF’s are associated with definite risk of solid tumors<br />

B.Anti-TNF’s are associated with definite risk of skin cancer<br />

C.Anti-TNF’s are associated with definite risk of lymphoma<br />

D.Anti-TNF’s are associated with definite risk of leukemia


I am on etanercept for my RA.<br />

Is it true that this drug can<br />

cause cancer<br />

You tell the patient:<br />

A. anti-TNF’s are associated with definite risk of solid tumors<br />

B. anti-TNF’s are associated with definite risk of skin cancer<br />

C. anti-TNF’s are associated with definite risk of lymphoma<br />

D. anti-TNF’s are associated with definite risk of leukemia


Malignancy in RA patients on anti-TNF’s –<br />

Conflicting Data<br />

* RR of lymphoma in RA pt’s compared to general population is 2.0<br />

• melanomatous and non-melanomatous cancer increased in RA pt<br />

on anti-TNF, odds ratio 1.5 and 2.3 respectively 1<br />

• conflicting data on risk of lymphoma in RA pt on anti-TNF 2<br />

• conflicting data on risk of solid tumors in RA pt on anti-TNF 3<br />

1<br />

Wolfe, <strong>Arthritis</strong> Rheum. 2007. (53,000 pts)<br />

2<br />

Bongartz, JAMA. 2006. (3,500 pt’s – increased lymphoma risk)<br />

2<br />

Askling, Ann Rheum Dis. 2005. (53,000 pts – no increased lymphoma risk)<br />

3<br />

Geborek, Ann Rheum Dis. 2005 (800 pts – increased risk of solid tumors)<br />

3<br />

Bongartz, JAMA. 2006. (3,500 pts – increased risk of solid tumors)<br />

3<br />

Askling, Ann Rheum Dis. 2005 (53,000 pts – no increased risk of solid tumors)<br />

3<br />

Wolfe, <strong>Arthritis</strong> Rheum. 2007. (53,000 pts – no increased risk of solid tumors)


I am on infliximab for RA and am<br />

travelling to South America. Can I<br />

get the yellow fever vaccine


I am on infliximab for RA and am<br />

travelling to South America. Can I<br />

get the yellow fever vaccine<br />

NO!<br />

No live viral vaccines for patients on biologics:<br />

• yellow fever<br />

• MMR<br />

• zoster, varicella<br />

• oral polio<br />

• small pox


Immunization with biologic therapies in RA<br />

RECOMMENDED:<br />

• Tetanus<br />

• Diphtheria<br />

• Inactivated polio<br />

• Pneumococcal<br />

• Influenza<br />

• Hepatitis B<br />

CONTRAINDICATED:<br />

• Oral polio *<br />

• Yellow fever<br />

• MMR<br />

• Varicella<br />

• Small pox *<br />

• Zoster<br />

* Should not be used in household<br />

contacts, avoid contact for 1 month


I am on methotrexate and<br />

hydroxychloroquine for RA. Are there<br />

any vaccines I cannot get


I am on methotrexate and<br />

hydroxychloroquine for RA. Are there<br />

any vaccines I cannot get<br />

NO!<br />

All vaccines (live, killed, attenuated) are safe in patients on nonchemotherapy<br />

doses of non-biologic DMARDs including:<br />

• methotrexate (< 0.5 mg/kg/wk)<br />

• hydroxychloroquine<br />

• leflunomide<br />

• azathioprine (< 3 mg/kg/day)<br />

Lacaille D, <strong>Arthritis</strong> Rheum. 2008.


I have been on Remicade<br />

(infliximab) for 5 years, can I<br />

get off of it


I have been on Remicade<br />

(infliximab) for 5 years, can I<br />

get off of it<br />

Maybe… it’s worth a try.


When biologic discontinued after remission achieved:<br />

• Sustained remission in 50-70% of patients, 2-7<br />

years after stopping infliximab<br />

• Best predictors of sustained remission are early<br />

treatment with and response to biologics<br />

• My empiric approach: taper off biologic once<br />

sustained clinical remission achieved by cutting<br />

dose in ½, increasing interval between doses<br />

van den Broek, Ann Rheum Dis. 2011.<br />

Tanaka, Ann Rheum Dis. 2010.<br />

Van der Kooij, Ann Rheum Dis. 2009.


I have viral hepatitis and<br />

seropositive (RF+/CCP+)<br />

rheumatoid arthritis. Is it safe<br />

to start Humira (adalimumab)<br />

A. OK to treat with anti-TNF in hepatitis B<br />

B. OK to treat with anti-TNF in hepatitis C<br />

C. OK to treat with anti-TNF in hepatitis B and C<br />

D. Not OK to treat with anti-TNF in hepatitis B or C


I have viral hepatitis and<br />

seropositive (RF+/CCP+)<br />

rheumatoid arthritis. Is it safe<br />

to start Humira (adalimumab)<br />

A. OK to treat with anti-TNF in hepatitis B<br />

B. OK to treat with anti-TNF in hepatitis C<br />

C. OK to treat with anti-TNF in hepatitis B and C<br />

D. not OK to treat with anti-TNF in hepatitis B or C


Anti-TNF’s are safe in hep C, not hep B<br />

• anti-TNF’s do not increase LFT’s or hep C viral load<br />

• anti-TNF’s can be started before or during anti-viral<br />

therapy for hepatitis C<br />

• anti-TNF’s delay the clearance of hep B<br />

• anti-TNF’s may lead to reactivation of latent hep B<br />

• all HBsAg+ patients should receive antiviral<br />

therapy prior to or together with the initiation of<br />

immunosuppressive therapy<br />

J Hepatol 2009.<br />

Roux CH, Rheumatology. 2006.<br />

Peterson JR, Ann Rheum Dis. 2003.


Take Home Messages<br />

1. Smoking increases risk and severity of RA<br />

2. Anti-TNF’s have definite risk of skin cancer and infection,<br />

possible risk of lymphoma or solid tumors<br />

3. Make sure patient is PPD negative before starting biologic<br />

4. No live viral vaccines for patients on biologics<br />

5. Anti-TNF’s are safe in active hepatitis C, not active hepatitis B

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!